Medcheck:A novel software for automated de-formulation of traditional Chinese medicine(TCM)prescriptions by liquid chromatography-mass spectrometry

Prescriptions are the main clinical application of traditional Chinese medicines(TCMs).Common forms include Chinese patent medicines,Kampo formulas,and hospital decoctions.A new pre-scription called“famous classical formulas”is recently developed and expected to boom in the market.Identifying constituent me-dicinal plants in prescriptions is critical for new drug development and quality control[1],which could avoid safety issues from adulteration or substandard ingredients,as seen in the notorious Longdan Xiegan Pill event.

Renin-angiotensin system inhibitors prescriptions in Chinese hospitalized chronic kidney disease patients

BACKGROUND Many guidelines have recommended renin-angiotensin system inhibitors(RASI)as the first-line treatment for patients with chronic kidney disease(CKD).We studied RASI prescription trends from 2010 to 2019,and analyzed the characteristics associated with RASI prescription in Chinese hospitalized CKD patients.AIM To study the prescription of renin angiotensin system inhibitors in hospitalized patients with CKD in China.METHODS It was retrospectively,cross-sectional reviewed RASI prescriptions in hospitalized CKD patients in China from 2010 to 2019.RASI prescribing trends were analyzed from 2010 to 2019,and bivariate and multivariate logistic regression analyses were conducted to identify characteristics associated with RASI prescription.RESULTS A total of 35090 CKD patients were included,with 10043(28.6%)RASI prescriptions.Among these patients,18919(53.9%)met the criteria for RASI treatments based on the 2012 kidney disease:Improving global outcomes guidelines.Of these,7246(38.3%)patients received RASI prescriptions.RASI prescriptions showed an initial rapid increase from 2011 to 2012,reached its peak around 2015 and 2016,and then exhibited a subsequent slight decreasing trend.Both bivariate and multivariate analyses showed that several characteristics,including the male gender,age less than 60-year-old,nephrology department admission,lower CKD stage,history of hypertension or diabetes,proteinuria,glomerulonephritis as the CKD etiology,and non-acute kidney injury were associated with RASI prescriptions.CONCLUSION The frequency of RASI prescriptions showed an initial increase but a slight decreasing trend in more recent years.CKD patients with certain characteristics such as elderly age,advanced disease stage,surgery department admission,or acute kidney injury were less likely to receive RASI prescriptions.In the application of RASI in hospitalized CKD patients is insufficient.The actual clinical practice needs to be improved.The development of related research is helpful to guide the correct choice of clinical treatment strategy.

Clinical research report on traditional Chinese patent medicines and traditional Chinese classic famous prescriptions(2022)

Objective:The paper is to comprehensively summarize and analyze the basic situation and methodological quality of clinical randomized controlled trials(RCTs)of traditional Chinese patent medicines and traditional Chinese classic famous prescriptions published in 2022,to provide evidence and reasonable suggestions for the advancement of clinical research and the formulation of policies and guidelines.Methods:The Evidence Database System of clinical evidence-based evaluation of traditional Chinese medicine was searched,and data from China National Knowledge Infrastructure(CNKI),PubMed,and other databases were supplemented.The search duration was from January 1,2022,to December 31,2022.RCTs of traditional Chinese patent medicines and traditional Chinese classic famous prescriptions were included as the source of clinical evidence,and published information,sample size,intervention,control measures,treatment course,methodological quality,and key link report were analyzed and evaluated.Results:A total of 1,464 RCTs of traditional Chinese patent medicines were included,which comprised 667 types of traditional Chinese patent medicines;“traditional Chinese patent medicines+Western medicine vs.Western medicine”was the most widely used intervention and control setting,involving 417 RCTs(28.48%).A total of 245 RCTs of traditional Chinese classic famous prescriptions were included,comprising 55 types of traditional Chinese classic famous prescriptions.“Decoction+conventional treatment vs.conventional treatment”was the most widely used intervention and control setting,with 87 RCTs(35.51%).Published RCTs on traditional Chinese patent medicines and traditional Chinese classic famous prescriptions were limited by the study design and implementation.Most“allocation concealment”and“blinding of patients and personnel”were rated as medium to high risk.There are insufficient reports on key research links such as experimental registration and ethical approval.Conclusions:The number of RCTs on traditional Chinese patent medicines has decreased in 2022,but there has been a slight improvement in the research quality and impact.There are relatively few studies on traditional Chinese classic famous prescriptions.Measures must be taken to improve clinical trial design,implementation,and reporting.Methodological experts should be invited to provide professional technical guidance on the trial design.In the research implementation process,attention should be paid to quality control,particularly the standardization of the randomized execution.

Clinical Observation of Chinese Medicinal Prescriptions for Swelling and Pain in The Postoperative Treatment of Mixed Hemorrhoids

Objective:To observe the clinical effect of traditional Chinese medicine(TCM)on reducing swelling and pain in patients with mixed hemorrhoids.Methods:Sixty patients with mixed hemorrhoids who were admitted to the Hospital of Traditional Chinese Medicine of Qiqihar from January 2023 to January 2024 were selected and divided into two groups.The treatment group(n=30)was treated with mixed hemorrhoid ligation combined with traditional Chinese swelling and pain medicine,and the control group(n=30)was only treated with mixed hemorrhoid ligation.The pain level,edema score,and prognosis of the two groups after the intervention were analyzed.The clinical efficacy was used as the evaluation criterion to compare the clinical effects of different treatment options.Results:After the treatment,the pain score,edema score,and prognostic wound score of the treatment group were all lower than those of the control group(P 0.05).The total clinical effectiveness of the treatment group(100%)was higher than that of the control group(76.67%),(χ^(2)=4.2857,P<0.05).Conclusion:The application of traditional Chinese swelling and pain medicine in treating patients with mixed hemorrhoids effectively reduced the patient’s pain,reduced the degree of wound edema,promoted wound healing,and improved the patient’s prognosis.The curative effect was significant and had a positive impact.

Exploring the compatibility theory of traditional Chinese medicine formulae:the disassembled prescriptions study

Traditional Chinese medicine(TCM)has become very popular in the treatment of complex diseases worldwide in recent decades.Despite the promising performance of TCM,how herbs work synergistically in a formula and their therapeutic targets remain ambiguous.This largely limits the correct use and modernization of TCM formulas clinically.The study of disassembled prescriptions is important for investigating the compatibility theory of Chinese medicines.By dissecting the mechanisms of TCM formulae,the compatibility principles of some well-known formulae,such as Realgar-Indigo naturalis,have been elucidated to a certain extent.In this review,several common methods of disassembled prescription studies are summarized,including those of single herb or mineral,sub-prescription,active ingredients or effective parts,large formulae,and systems pharmacology studies,as well as the methods of grouping based on the properties or efficacy of Chinese medicines,in order to provide evidence for formulae study.Moreover,some challenges to be addressed in disassembled prescriptions studies have been identified in this review.

Compatibility Rules of Prescriptions of Tibetan Medicine Polygonatum cirrhifolium Based on Data Mining

[Objectives]To study the prescription compatibility rules of the Tibetan medicine Polygonatum cirrhifolium(Polygonati Rhizoma,Huangjing)based on data mining,so as to provide data support for clinical application and new drug development.[Methods]Prescriptions containing Tibetan medicine Huangjing were collected from Tibetan Medicine Prescriptions Encyclopedia and Tibetan Medicine Classic Literature Collection.The Traditional Chinese Medicine Inheritance Computing System(TCMICS 3.0)and R version 4.1.3 were used to mine and analyze the compatibility rules of prescriptions containing Tibetan medicinal material Huangjing,the rules of medication for high-frequency diseases,and the association rules of various medicinal materials.[Results]A total of 124 prescriptions were collected from the classic literature of Tibetan medicine,and the frequency statistical analysis showed that drugs compatible with Huangjing(≥15)included Tianmendong(Root of Cochinchinese Asparagus)(80),Mirabilis himalaica(Edgew.)Heimerl(Himalayan purple jasmine)(72),Jili(Tribuli Fructus)(70),Tibetan Aoruqin(Vicatia coniifolia)(58),Baidoukou(Round Cardamom Fruit)(47),Hezi(Chebulae Fructus)(45),Shouzhangshen(Rhizome of Conic Gymnadenia)(28),Yuganzi(Phyllanthi Fructus)(26),Pomegranate(25),Maohezi(Terminaliae Belliricae Fructus)(24),Zicaorong(Lacca)(23),Rougui(Cinnamomi Cortex)(15).The main diseases were yellow water disease(20),gynecological diseases(19),kidney cold disease(17),and other Tibetan medicine diseases.Association rule analysis showed that the drug combinations with the highest frequency were Huangjing—Tianmendong,Huangjing—Himalayan purple jasmine,and Huangjing—Jili.[Conclusions]The frequency of combined use of Tibetan medicine Huangjing with dry yellow water,tonifying kidney and diuresis,nourishing health,and treating gynecological diseases is relatively high.

Preliminary Investigation on Zhuang Folk Medicated Bath Prescriptions:A Case Study of Hechi Region

This paper summarizes the mechanism,methods and characteristics of Zhuang folk medicated bath,as well as the composition and application of prescriptions,which provides a basis for the popularization of Chinese ethnic medicine.

Traditional Chinese medicine prescriptions and herbs for the treatment of hypothyroidism:a narrative review

The increasing prevalence of hypothyroidism,which can cause endocrine dysfunction,abnormal neurological function,and cardiovascular and cerebrovascular injuries,poses serious health problems.Thyroid hormone supplementation constitutes the current main therapeutic method for hypothyroidism,yet it has many limitations and risks and is not suitable for everyone.Therefore,it is necessary to seek alternative and complementary treatment methods.It has been proven in practice that traditional Chinese medicine(TCM)possesses multi-channel comprehensive characteristics for the treatment of hypothyroidism and has more advantages than single thyroid hormone supplementation.Through a comprehensive examination of existing literature about TCM efficacy in addressing hypothyroidism,we have meticulously consolidated the most recent research findings on prescriptions and herbal substances employed in the treatment of this condition.Furthermore,we have explicated their respective functions in the management of hypothyroidism,thereby offering valuable perspectives and recommendations for the prospective utilization of natural remedies in its treatment.

Compatibility Rules of Prescriptions of Tibetan Medicinal Material Mirabilis himalaica(Edgew.)Heimerl Based on Data Mining

[Objectives]To study the prescription compatibility rules of the Tibetan medicinal material Mirabilis himalaica(Edgew.)Heimerl(Himalayan purple jasmine)based on data mining,and to provide reference for clinical application and new drug development.[Methods]The literature data were collected and the prescriptions containing Himalayan purple jasmine were sorted and classified by Microsoft Excel 2019 software.The Traditional Chinese Medicine Inheritance Computing System(TCMICS 3.0)was used to statistically analyze the high-frequency drugs and core drug combinations,the frequency of disease treatment,and the rules of"tastes transforming flavors"of drugs.The FP-tree algorithm was used to analyze the association rules among various Tibetan medicinal materials in the prescriptions,and different supports were set to analyze the compatibility rules of the prescriptions.[Results]There were a total of 129 prescriptions containing Himalayan purple jasmine,297 medicinal materials used in combination with it,and 34 Tibetan medicinal materials with a frequency of≥15.The medicinal flavors were mostly sweet,bitter,and pungent.Among the three flavors,bitterness and sweetness were the majority.At the same time,the medicinal properties were blunt,soft,cool,and warm.A total of 130 kinds of diseases were involved,among which 8 kinds of diseases such as gynecology,kidney cold and yellow water disease had a high frequency.Through association rule analysis,33 commonly used core drug combinations were obtained.The support,confidence,and frequency of the five drug combinations[Jili(Tribuli Fructus),Huangjing(Polygonati Rhizoma),Tianmendong(Root of Cochinchinese Asparagus),and Tibetan Aoruqin(Vicatia coniifolia)]→Himalayan purple jasmine were the basic prescription of Tibetan medicine Wudagen Powder.The drug combinations with higher confidence included Bibo(Piperis Longi Fructus)→Himalayan purple jasmine,Pomegranate(Punica granatum→Himalayan purple jasmine,Baidoukou(Round Cardamom Fruit)→Himalayan purple jasmine,Hezi(Chebulae Fructus)→Himalayan purple jasmine.Jili(Tribuli Fructus)→Himalayan purple jasmine,Huangjing(Polygonati Rhizoma)→Himalayan purple jasmine and Tianmendong(Root of Cochinchinese Asparagus)→Himalayan purple jasmine had highest frequency.[Conclusions]Through the TCMICS,this paper analyzed the compatibility rules of commonly used drugs containing Himalayan purple jasmine and the characteristics of the main diseases.It can be seen that Himalayan purple jasmine is sweet in taste and warm in nature.It assists sovereign drugs in the form of ministerial drugs,which enhances the effect of regulating"long"and nourishing,and plays the role of regulating"long",dispelling cold,and reconciling various drugs,which embodies the compatibility rules of sovereign and ministerial drugs of Tibetan medicines.The main diseases of Himalayan purple jasmine are related to"long"regulation,and it is mostly used in the treatment of gynecological diseases after being combined with other drugs to form a prescription.Most drugs in the prescriptions are sweet,which is the therapeutic principle of regulating"long"and nourishing,and verifies the scientific and rational principle of clinical use of Tibetan medicine.In the prescription,the medicinal properties include both warm and cool,and the medicinal taste is sweet and bitter,which is in line with the compatibility theory of"tastes transforming flavors"in traditional Tibetan medicine prescriptions.

Comparing the mechanism of four classic Gualou-Xiebai prescriptions for cardiovascular diseases with phlegm and blood stasis syndrome based on molecular network modeling

Background:Four classical Traditional Chinese Medicine prescriptions,namely Gualou Xiebai Baijiu decoction,Gualou Xiebai Banxia decoction(GLXBBX),Zhishi Xiebai Guizhi decoction(ZSXBGZ)and Danlou prescription(DL),have been frequently used for treatment of phlegm and blood stasis syndrome(PBSS)-related cardiovascular diseases.However,its therapeutic mechanism has not been clearly elucidated.This study aimed to explore PBSS and its molecular mechanism,clarify and compare the mechanisms of four prescriptions in treating PBSS-related diseases.Method:In this study,we collected four prescriptions’compounds,predicted therapeutic targets,and enriched pathways which were based on network pharmacology.Then,we analysed the commen and different mechanisms by combing the network of components,targets and pathways.Finally,molecular docking was engaged to assess the binding potential of key compounds and hub targets.Results:We showed that four prescriptions’intersection genes(VEGFA,SRC,EGFR,etc.)were commonly enriched in PI3K-AKT signaling pathway,HIF-1 signaling pathway,etc.In addition,platelet activation and cAMP signaling pathway were singly enriched from the GLXBBX through unique compounds 12,13-epoxy-9-hydroxynonadeca-7,10-dienoic acid and Cyclo(L-tyrosyl-L-phenylalanyl).These bioactive compounds may exert GLXBBX’s unique pharmacological pathways via involving in mediating PPARA,PTGER3,etc.Sphingolipid signaling pathway was singly enriched from the ZSXBGZ through unique compounds tetramethoxyluteolin,ergosterol peroxide,etc.These bioactive compounds could mediate ADORA1,ADORA3 and TNFRSF1A to regulate ZSXBGZ’s unique pharmacological pathways.AMPK signaling pathway was singly enriched from the DL through unique compounds kaempferol,evofolinb,ethyl acid and aureusidin.These bioactive compounds were involved in mediating the main targets of AMPK signaling pathway,such as TNF,TNFRSF1A,etc.Conclusions:Our research demonstrated that GLXB-prescriptions involved in almost all pathological stages of PBSS-related cardiovascular diseases by modulating high-frequency shared pathways and targets mainly through key compounds(quercetin,mandenol,sitosteryl acetate and luteolin,etc.),for example,participate in the process of atherosclerosis,lipid metabolism,inflammation,immune response,thrombosis,inhibit inflammatory factors and platelet aggregation,regulate immune function,vascular function,oxidative stress.In addition to common pharmacological efficacies,there could also be specificities among GLXB prescriptions due to different compounds.For example,GLXBBX tends to regulate the function of vascular and endothelial barrier,prevent thrombosis.ZSXBGZ tends to regulate lipid metabolism and protect the heart from lipid accumulation.DL tends to maintain energy homeostasis and improve inflammation.

《伤寒论》临证价值刍议

《伤寒论》临证思想研究者众多,已逐渐形成较为完善的伤寒学研究体系,然尚存不足之处,如对此书临床价值认识不全面、疫病诊治重温病轻伤寒、经典理论应对当代疾病及经方运用存在的问题等。提出《伤寒论》为百病立法,治伤寒亦治杂病;疫病诊治重温病轻伤寒,实则寒温相互羽翼;经典研究可借鉴西医思维,应对疾病须以中为基;目前经方运用重方药略理法,亟待构建规范体系等观点,为中医经典临床研究提供思路。

苓桂剂类方方证分析与传承创新

苓桂剂类方是仲景基于水气病而设的,以茯苓、桂枝为主要配伍的一类组方。仲景经典的苓桂剂类方有7个,分别是苓桂术甘汤、苓桂枣甘汤、苓桂姜甘汤、苓桂味甘汤、五苓散、茯苓泽泻汤和防己茯苓汤。对苓桂剂的7个类方方证进行了系统梳理,从组方配伍、以方测证、方证对应、核心病机等方面进行了比较和分析,然后介绍了叶天士、刘渡舟和本研究团队对苓桂剂类方在传承中的丰富和发展。最后结合现代医学进展,总结了苓桂剂类方在临床的应用拓展与创新。传承是中医发展的基石,在传承中创新是中医赋予我们的使命,苓桂剂类方方证的传承是中医传承创新的典范。

基于古本草古方剂视角下黄柏隐性功能的文献考察与逻辑分析

目的 挖掘黄柏的隐性功能,扩大其现实应用范围。方法 通过历代主流本草文献考察分析黄柏的功能主治,同时利用《普济方》数据库管理系统,对黄柏进行跨病种检索,获得含黄柏复方在各种疾病中的分布情况,了解含黄柏复方所治病证的构成、各病证配伍此药频数。在此基础上,再与历代本草和2020版《中华人民共和国药典》记载的功能主治进行分析比较,依据频次统计分析与逻辑归纳判断,以获取对黄柏的药物传承和隐性功能的整体认识,借以发现黄柏业已失传的隐性功用,并通过论证扩大现实应用范围。结果 由历代本草文献中总结出来的解毒疗疮、泻火除蒸、清热燥湿等功用一直沿用至今,而散结消癥、定惊、安神、止渴、止血、止痛等功用至今鲜有应用。《普济方》数据库中含黄柏复方治疗癥瘕积聚、消渴、出血、疼痛等病症,《中华人民共和国药典》未曾收录。结论 结合现代药效学研究,初步确认黄柏的隐性功能是散结消癥、止渴、定惊、安神。

基于数据挖掘的痛经用药规律研究

目的:基于数据挖掘技术分析《中医方剂大辞典》中治疗痛经方剂的用药规律。方法:根据纳入与排除标准筛选出《中医方剂大辞典》中治疗痛经的方剂,对其进行方药名称规范,运用Excel、IBM SPSS Modeler 18.0、IBM SPSS Statistics 26.0等进行频数统计、关联规则分析、聚类分析及因子分析。结果:共纳入151首治疗痛经的方剂,涉及中药191味;其中出现频次≥10的中药为当归、川芎、延胡索、白芍、香附、甘草等共36味,药效以补虚药、活血化瘀药、理气药为主,药性偏温、寒、平,药味则偏辛、苦、甘,多入肝、脾、心经。选取出现频次≥25的13味高频药物进行关联规则分析,得到“当归-川芎“”当归-香附-川芎“”当归-熟地黄-白芍-川芎”等常用药对21组,并通过提升关联规则的支持度得到“当归-川芎-白芍”核心组合。进行高频药物聚类分析得出4类药物组合,C1:白芍、熟地黄、川芎、当归;C2:牡丹皮、茯苓;C3:香附、甘草;C4:桃仁、红花,因子分析得到5个公因子。结论《:中医方剂大辞典》中治疗痛经以补血活血、化瘀散结、疏肝理气为主。

祛瘀通络方联合灌汤1号对盆腔炎性疾病后遗症患者炎症因子的影响

目的探讨祛瘀通络方联合灌汤1号对盆腔炎性疾病后遗症患者炎症因子的影响。方法选取100例盆腔炎性疾病后遗症患者,随机分为对照组与治疗组,每组50例,对照组采用桂枝茯苓丸口服治疗,治疗组采用祛瘀通络方口服联合灌汤1号保留灌肠治疗,疗程3个月。观察中医证候积分、局部症状及血清白细胞介素-8(Interleukin-8,IL-8)、白细胞介素-6(Interleukin-6,IL-6)、肿瘤坏死因子(Tumor necrosis factor-α,TNF-α)变化。结果两组患者治疗前中医证候积分比较差异无统计学意义(P>0.05),治疗后中医证候积分较治疗前下降,治疗组下降程度明显大于对照组,比较差异有统计学意义(P<0.05);两组患者治疗前局部症状评分比较差异无统计学意义(P>0.05),治疗后局部症状的评分较治疗前下降,治疗组下降程度明显大于对照组,比较差异有统计学意义(P<0.05);两组患者治疗前血清IL-8、IL-6、TNF-α比较差异无统计学意义(P>0.05),治疗后IL-8、IL-6、TNF-α水平较治疗前下降,治疗组下降程度明显大于对照组,比较差异有统计学意义(P<0.05);治疗组治疗疗效明显优于对照组(P<0.05),治疗组治疗总有效率为96.00%(48/50),高于对照组80.00%(40/50),比较差异有统计学意义(P<0.05)。结论盆腔炎性疾病后遗症患者采用祛瘀通络方联合灌汤1号治疗,可改善自觉症状及妇科阳性体征,降低血清促炎因子水平,提高治疗疗效。

半夏泄心汤全方及其拆方联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对炎性因子水平的影响

目的:探究半夏泄心汤全方及其拆方联合美沙拉嗪治疗溃疡性结肠炎的应用效果。方法:选取2023年5月~2024年5月在吉林省人民医院消化科和中医科诊治的120例中度溃疡性结肠炎患者作为研究对象。随机分为对照组(24例)与观察组(96例)。观察组分为全方组、辛开组、苦降组、甘补组,每组24例。对照组与观察组同时给药美沙拉嗪肠溶片。连续治疗3个月,比较对照组与观察组治疗前后的肠道内窥镜及外周血血清炎性因子水平。记录药物的不良反应。结果:观察组与对照组均表现出不同程度的治疗效果。对照组美沙拉嗪可以通过抑制炎性反应达到治疗结肠炎的作用。半夏泻心汤及拆方联合美沙拉嗪治疗结肠炎表现出良好的效果。辛开组具有温暖中焦脾胃的功效,能够偏向缓解患者呕吐,腹痛等症状。苦降组由于具有较多生物碱、黄酮类成分,具有较强的止泻、抗菌、消炎的功效。甘补组虽然能够大补元气提高患者免疫力,但由于患者肠道功能退化,并不能起到良好的效果。结论:半夏泻心汤全方联合美沙拉嗪可以有效缓解结肠炎症状并提高疗效。不同组方偏向不同,但单纯运用甘补类药材,不适宜肠胃功能较差的患者。

泄浊养血法联合重组人促红素注射液治疗肾虚湿浊型慢性肾脏病3~5期肾性贫血患者的临床观察

[目的]观察泄浊养血法联合重组人促红素注射液对慢性肾脏病(CKD)3~5期肾性贫血患者贫血改善及残余肾功能的干预作用。[方法]选择2020年10月—2021年10月就诊于天津中医药大学第一附属医院的88例CKD 3~5期肾性贫血患者,根据随机数字表法随机分为对照组(44例)和治疗组(44例)。对照组予重组人促红细胞生成素注射液及多糖铁复合物治疗,治疗组在此基础上联合泄浊养血法中药方治疗,连续服用3个月,观察治疗前后两组临床疗效、红细胞计数(RBC)、血红蛋白(Hb)、血清肌酐(Scr)、尿素氮(BUN)、肾小球滤过率(eGFR)、尿微量白蛋白(mALB)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)的变化,症状积分及不良反应发生率。[结果]治疗3个月后,治疗组总有效率为86.36%,对照组为56.82%,治疗组临床疗效优于对照组(P<0.05);症状积分、RBC、Hb、Scr、BUN、mALB均较治疗前改善,且治疗组优于对照组(P<0.05);安全性指标中AST、ALT治疗前后数值变化,差异无统计学意义(P>0.05)。两组病例中均未出现不良反应。[结论]泄浊养血法联合重组人促红细胞生成素注射液治疗可以改善CKD 3~5期非透析肾性贫血患者临床症状,提高临床疗效,延缓肾功能进展,且具有一定的安全性。

论基于“病、证、征结合”方剂的主治表述

目前对方剂主治的规范性研究较少,通过对方剂主治源流的梳理并分析《方剂学》教材中方剂主治描述中存在的问题,提出“病、证、征结合”3个层次的方剂主治描述规范,从而有利于临证依法用方、规范教材和规范方剂的科学研究。

痔疮栓联合中药熏洗坐浴对混合痔术后疼痛水肿的治疗作用分析

【目的】探究痔疮栓联合中药熏洗坐浴对混合痔术后疼痛水肿的临床疗效。【方法】将62例拟行手术治疗的混合痔患者随机分为试验组和对照组,每组各31例。2组患者均给予混合痔手术治疗(高位套扎术或混合痔外剥内扎术)和术后常规护理,在此基础上,对照组给予痔疮栓塞肛治疗,试验组给予痔疮栓塞肛联合中药熏洗坐浴(中药熏洗方由红花、桃仁、延胡索、滑石、川楝子、枳壳、黄柏、没药、乳香等组成)治疗,疗程为2周。观察2组患者治疗前后疼痛程度评分和水肿程度评分的变化情况,比较2组患者的症状缓解时间、临床疗效及治疗满意度。【结果】(1)治疗2周后,试验组的总有效率为96.77%(30/31),对照组为80.65%(25/31),组间比较(χ2检验),试验组的疗效明显优于对照组,差异有统计学意义(P<0.05)。(2)治疗后,2组患者的疼痛程度评分和水肿程度评分均较治疗前明显降低(P<0.05),且试验组对疼痛程度评分及水肿程度评分的降低作用均明显优于对照组,差异均有统计学意义(P<0.01)。(3)试验组的疼痛消失时间和水肿消失时间均较对照组明显缩短,差异均有统计学意义(P<0.01)。(4)试验组的总满意率为96.77%(30/31),对照组为77.42%(24/31),组间比较(χ2检验),试验组的治疗满意度明显优于对照组,差异有统计学意义(P<0.05)。【结论】痔疮栓联合中药熏洗坐浴对混合痔术后疼痛水肿的治疗作用显著,可有效改善患者的水肿程度和疼痛感,促进机体康复,提高患者的治疗满意度。

门诊共济保障方式改革、零售药店发展与处方流转

职工医保门诊共济保障改革是完善基本医保制度的重大举措。本次改革将符合条件的定点零售药店纳入门诊统筹报销,为零售药店的高质量发展带来重大机遇。门诊共济保障改革以及零售药店实现高质量发展的关键环节是医院处方的流转。本文认为,处方流转的主要障碍一是处方管理及药品使用安全管理上的部门分割以及由此带来的风险责任冲突及利益冲突,二是零售药店本身的经营与管理模式还难以适应处方的风险管理要求。实现处方的畅通流转一是要坚持“三医”协同治理,建立处方管理及药品使用安全管理全链条监管机制,打破部门分割,充分尊重参与各方的管理要求及利益诉求;二是零售药店要转变运营模式,提升药事服务和商业服务能力,适应门诊共济保障改革后处方流转的要求。